Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,161 across all filing types
Latest filing 2018-12-18 Director's Dealing
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2018-12-18 English
FORM 3
Director's Dealing
2018-12-18 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 14, 2018, by PTC Therapeutics, Inc. The key content is the appointment of two new directors to the company's board, including their biographies, terms, and compensation details. The document specifically includes Item 5.02, which relates to the departure or appointment of directors or certain officers. There is no financial data or report content, but rather an announcement of management changes. This fits the category of Board/Management Information (MANG). The document length is 8360 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the classification is MANG with high confidence.
2018-12-18 English
10-Q
Interim / Quarterly Report Q3 2018
2018-11-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 5, 2018, by PTC Therapeutics, Inc. It announces the financial results for the quarter ended September 30, 2018, and references a press release (Exhibit 99.1) containing the full text of the announcement. It also mentions a conference call and a slide deck to be posted on the company's website. The document itself is a current report announcing quarterly financial results, not the full quarterly report or detailed financial statements. The length is 4274 characters, which is relatively short and consistent with an earnings release or announcement. The key section is Item 2.02 "Results of Operations and Financial Condition," which is typically used for earnings releases. Therefore, the document is best classified as an Earnings Release (ER).
2018-11-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce unscheduled material events or corporate changes. The text includes a description of an event related to supplemental information on a clinical study and references a press release attached as an exhibit. The document is short (3351 characters) and primarily serves as an announcement of an event and the attached press release, not a full financial report or detailed filing. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-10-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.